Introduction {#sec1}
============

Multipotent mesenchymal stromal cells (MSCs) are a population of multilineage progenitor cells that were first isolated from the bone marrow ([@bib15; @bib35]). These somatic progenitor cells harbor the capacity to differentiate into adipocytes, osteoblasts, and chondrocytes, as well as a number of extramesodermal lineages ([@bib37]). Recent studies have demonstrated that MSCs exert strong immunomodulatory effects on multiple populations of leukocytes via various mechanisms, including suppression of CD4 and CD8 lymphocyte proliferation and responses, induction of T regulatory lymphocytes (Tregs; a population of immunomodulatory T cells), and secretion of immunosuppressive molecules such as transforming growth factor-β (TGF-β) and indoleamine-2,3-dioxygenase (IDO) ([@bib50]). MSCs also strongly suppress natural killer lymphocyte cytotoxicity and affect dendritic cell (DC) maturation, e.g., by inhibiting the differentiation of monocytes to immature myeloid DCs and decreasing the effector functions of plasmacytoid DCs ([@bib26; @bib50]). Many of these components are similar to the immunomodulatory armamentarium of the immune system, which is important for preventing autoimmunity and establishing tolerance ([@bib19; @bib51]), with mechanisms ranging from anti-inflammatory molecules such as TGF-β, IDO, and interleukin-10 (IL-10) to leukocyte subpopulations such as Tregs and tolerogenic DCs ([@bib30; @bib40; @bib47]).

As with many biological phenomena, immunomodulation is a double-edged sword, and many of these tolerogenic mechanisms appear to be manipulated by cancer cells to create an immunoprivileged niche to further their own growth ([@bib38]). One of the most prominent immunomodulatory leukocyte subpopulations in cancer consists of myeloid-derived suppressor cells (MDSCs) ([@bib34]). Derived from myeloid precursors, MDSCs suppress immune response by a number of mechanisms, such as suppressing cytotoxic lymphocyte effector functions and targeting T cells by expressing the enzymes arginase 1 (ARG1) and inducible nitric oxide synthase (iNOS), both of which block the production of the T cell CD3-ζ chain by metabolizing L-arginine ([@bib16; @bib17]). Human and mouse studies have revealed that chronic inflammation and proinflammatory mediators such granulocyte macrophage colony-stimulating factor (GM-CSF), IL-1β, IL-6, and prostaglandin E~2~ (PGE~2~) are involved in the induction of these suppressor leukocytes ([@bib4; @bib41; @bib45; @bib55]). Although it is clear that the tumor microenvironment is maintained by diverse cell types, the role of secreted factors other than cytokines and proinflammatory factors in the expansion of MDSCs has largely been unexplored, with the exception of vascular endothelial growth factor ([@bib14; @bib43]). We report that MDSCs can be expanded by MSC-secreted hepatocyte growth factor (HGF), a potent mitogenic growth factor.

Results {#sec2}
=======

MSCs Can Expand High Numbers of Functional CD14^−^CD11b^+^CD33^+^ MDSCs from Peripheral Blood Leukocytes {#sec2.1}
--------------------------------------------------------------------------------------------------------

We hypothesized that the strong immunosuppressive properties of diverse sources of MSCs extend to involve the expansion of MDSCs. We first isolated and cultured MSCs from placenta and bone marrow, and then characterized the cells for surface marker expression and multilineage differentiation potential. Both bone marrow and placental MSCs are positive for surface expression of CD73, CD105, and CD90, but negative for hematopoietic markers such as the costimulatory molecules CD80 and 86 ([Figure 1](#fig1){ref-type="fig"}A; [@bib6; @bib50; @bib54]). Both populations of MSCs can differentiate into osteoblastic, chondrogenic, and adipocytic lineages, and thus meet the criteria for multipotent MSCs ([Figure 1](#fig1){ref-type="fig"}B; [@bib11; @bib29; @bib35]).

To test whether MSCs can expand MDSCs, we cocultured MSCs with human peripheral blood leukocytes (PBLs) and assayed for MDSCs, which in the human system are most commonly characterized as CD14^−^CD11b^+^CD33^+^ leukocytes with a strong suppressor function ([@bib34; @bib36]). We found that both bone marrow and placental MSCs could increase the number of CD14^−^CD11b^+^CD33^+^ cells from PBLs ([Figure 2](#fig2){ref-type="fig"}A). Both cell percentage and numbers were increased significantly after PBL coculture with MSCs, with CD11b^+^ cells showing an increase from a baseline of 8.9% ± 0.6% (10,179 ± 926 cells; averages ± SEM) to 19.2% ± 1.2% (19,508 ± 1,258 cells) after coculture with MSCs, and CD14^−^CD11b^+^CD33^+^ cells increasing from 1.3% ± 0.1% (1,052 ± 90 cells) at baseline to 2.4% ± 0.2% (2,343 ± 147 cells) after coculture with MSCs ([Figure 2](#fig2){ref-type="fig"}B). To assess whether these MSC-expanded MDSCs were functional, we sorted MSC-induced CD14^−^CD11b^+^CD33^+^ cells and cocultured these cells with allogeneic proliferating lymphocytes to assess for suppressive capacity. We found that the MSC-expanded CD14^−^CD11b^+^CD33^+^ cells could suppress lymphocyte proliferation in a dose-dependent manner ([Figure 2](#fig2){ref-type="fig"}C). Human MDSCs are known to express ARG1 and iNOS ([@bib33; @bib39]), and we found that MSC-induced MDSCs also expressed these enzymes and at significantly higher cell numbers compared with baseline ([Figures 2](#fig2){ref-type="fig"}D and 2E, respectively). MDSCs have also been shown to express IL-10 and TGFβ in some reports ([@bib36]), but we did not find any expression of these molecules at baseline or after MSC coculture ([Figure S1](#app2){ref-type="sec"}A available online). CD14^−^CD11b^+^CD33^+^ MDSCs have been reported to induce Tregs ([@bib12; @bib20]), and we also found that MSC-induced CD14^−^CD11b^+^CD33^+^ cells were able to induce high numbers of CD4^+^CD25^high^CD127^low^ Tregs from stimulated PBL ([Figures 2](#fig2){ref-type="fig"}F and [S1](#app2){ref-type="sec"}B). Thus, MSC-expanded CD14^−^CD11b^+^CD33^+^ cells have multiple immunomodulatory functions.

Expansion of MDSCs by MSCs Is Mediated by Secreted HGF {#sec2.2}
------------------------------------------------------

We next investigated the mechanisms involved in MSC expansion of MDSCs. We found that the expansion of MDSCs by MSCs was not affected by transwell separation of cells, indicatig that cell-cell contact was not needed and implicating secreted factors in this process ([Figure 3](#fig3){ref-type="fig"}A). We therefore analyzed the conditioned medium of MSCs to assess for relevant secreted molecules. MSCs secrete a number of stromal-related factors, such as RANTES/CCL5, HGF, and IL-6, the latter of which has been implicated in the expansion of MDSCs ([@bib4]; [Figure 3](#fig3){ref-type="fig"}B). However, using both blocking antibodies and small interfering RNA (siRNA) knockdown studies, we did not find that IL-6 contributed to the expansion of MDSCs by MSCs ([Figure S2](#app2){ref-type="sec"}).

It was previously reported that STAT3 is critical for the expansion of MDSCs ([@bib16]). STAT3 is also an important molecule in the signal transduction pathway of HGF ([@bib49]), a molecule that is known to be highly secreted by many cell types, including MSCs ([@bib8; @bib48; @bib49]). Since we also found that HGF was highly secreted by MSCs ([Figure 3](#fig3){ref-type="fig"}B), we assessed whether this molecule is involved in MSC expansion of MDSCs. We found that the addition of recombinant HGF alone could result in the expansion of MDSCs, and this effect was dose dependent up to a concentration of 30 ng/ml ([Figure 3](#fig3){ref-type="fig"}C), which is approximately the upper limit found in MSC-conditioned medium ([Figure 3](#fig3){ref-type="fig"}B). HGF-expanded MDSCs also expressed iNOS and ARG1, and at higher cell numbers compared with baseline ([Figure 3](#fig3){ref-type="fig"}D). Moreover, HGF-expanded MDSCs can suppress allogeneic lymphocytes proliferation as well ([Figure 3](#fig3){ref-type="fig"}E). To further ascertain the involvement of HGF in MSC expansion of MDSCs, we suppressed the secretion of HGF by MSCs with siRNA. Using siRNA specific for HGF, we were able to effectively suppress the secretion of the molecule by MSCs, and this abrogated the expansion of MDSCs by MSCs ([Figure 3](#fig3){ref-type="fig"}F). Thus, our data support that HGF secreted by MSCs is involved in the expansion of MDSCs.

HGF is a well-known and important mitogen for cancer cell growth ([@bib31]). Because MDSCs play a critical role in creating the immunoprivileged niche of tumors, we assessed whether cancer cell lines that secrete high levels of HGF could expand higher numbers of MDSCs. We found that, indeed, the level of HGF secreted by several cell lines correlated with the number of MDSCs expanded ([Figures 4](#fig4){ref-type="fig"}A and 4B). We then assessed the role of MSC-secreted HGF in the in vivo setting of the tumor microenvironment. When mice were inoculated with tumor cells admixed with MSCs silenced for HGF expression, there was a significant reduction in tumor-associated Gr-1^+^CD11b^+^ MDSCs ([Figure 4](#fig4){ref-type="fig"}C). Moreover, in both wild-type C57BL/6 and BALB/c mice, we found that the liver, an organ that is known to secrete high levels of HGF, contained a significantly higher proportion of Gr-1^+^CD11b^+^ MDSCs than the spleen ([Figure 4](#fig4){ref-type="fig"}D). Furthermore, when we inhibited the HGF/c-Met pathway in wild-type mice by injecting PHA-665752 (a second-generation c-Met inhibitor; [@bib7]), we observed a significant decrease in hepatic, but not splenic, MDSCs, even after we excluded other myeloid cells, such as macrophages and Kupffer cells (resident hepatic macrophages), using the surface marker F4/80 ([@bib24; @bib25]; [Figures 4](#fig4){ref-type="fig"}E and [S3](#app2){ref-type="sec"}). Critically, the HGF/c-Met pathway appears to be responsible for the high numbers and vast majority of hepatic Gr-1^+^CD11b^+^F4/80^−^ MDSCs, since c-Met inhibition resulted in a significant loss of ∼70% of this population ([Figure 4](#fig4){ref-type="fig"}E), which was not observed for splenic MDSCs. These results are highly suggestive of a critical role for HGF in maintaining the high numbers of MDSCs in the liver. To further validate the in vivo relevance of our findings, we injected recombinant HGF intravenously into wild-type C57BL/6 mice. After 3 days, we found a significant increase of Gr-1^+^CD11b^+^ MDSCs in the bone marrow (where myeloid cells are most abundant; [@bib17]) of these mice ([Figure 4](#fig4){ref-type="fig"}F), indicating that HGF can expand MDSCs in an in vivo setting. Collectively, these results indicate the relevance of HGF in tumor-associated MDSCs and in vivo settings.

Expansion of MDSCs by HGF Is Mediated by the HGF Receptor c-Met and Increased Phosphorylation of STAT3 {#sec2.3}
------------------------------------------------------------------------------------------------------

To investigate the mechanism behind HGF-mediated expansion of MDSCs, we checked for expression of c-Met, the cognate receptor for HGF ([@bib5; @bib49]), on MDSCs. We found that CD14^−^ leukocytes and MDSCs constitutively expressed low levels of c-Met ([Figures 5](#fig5){ref-type="fig"}A and [S4](#app2){ref-type="sec"}), and when c-Met on PBLs was blocked with neutralizing antibodies, the expansion of MDSCs by HGF was abrogated ([Figure 5](#fig5){ref-type="fig"}B). To investigate whether the effects of the HGF/c-Met axis were mediated through STAT3, we checked for HGF-induced STAT3 phosphorylation, which indicates activation of the pathway, in MDSCs. We found that exogenous addition of HGF induced an increase over baseline levels of phosphorylated STAT3 (pSTAT3), most consistently and significantly at 1 hr after treatment ([Figures 5](#fig5){ref-type="fig"}C and [S5](#app2){ref-type="sec"}). Moreover, when the STAT3 inhibitor cpd188 was added in the presence of exogenous HGF, the expansion of MDSCs was abrogated in a dose-dependent fashion ([Figure 5](#fig5){ref-type="fig"}D). Thus, HGF mediates the expansion of MDSCs by binding to its receptor, c-Met, which leads to increased phosphorylation of STAT3 ([Fig. 6](#fig6){ref-type="fig"}).

Discussion {#sec3}
==========

Recent reports have highlighted MDSCs as a prominent leukocyte subpopulation involved not only in tumor-associated immune suppression but also in regulation of the immune system at large ([@bib2; @bib16; @bib39]). Previous data have shown that a number of proinflammatory mediators are important inducers of these cells, but there has been no report regarding the involvement of tumor-associated mitogenic growth factors in the process. Our data link HGF secreted by MSCs to the expansion of MDSCs. Our findings can help to explain the strong association of MDSCs with tumors, since it is well established that in the tumor microenvironment, HGF is highly secreted by both the cancer cells themselves and the supporting stromal cells, promoting cell survival and tumor growth ([@bib5; @bib31]). While HGF has been implicated in immunoregulatory responses ([@bib3; @bib8]), and the liver, which naturally secretes high levels of HGF, was reported to have some immunological functions ([@bib42]), the specific molecular mechanisms underlying these observations have been largely unexplored and the reported effects have not been consistently replicated ([@bib27]). Our finding that high numbers of hepatic MDSCs in mice can be significantly altered by disruption of the HGF/c-Met pathway sheds some mechanistic light on this issue, and, overall, our data demonstrate that HGF mediates the expansion of functional MDSCs by engaging c-Met, its receptor, and increasing the phosphorylation of STAT3, one of its downstream molecules.

The immunomodulatory properties of MSCs have been highlighted as being therapeutic for autoimmune diseases and other immune-related diseases such as graft-versus-host disease ([@bib1; @bib10; @bib22; @bib28]). As exciting as these findings are, some researchers have noted that the same immunomodulatory effects of MSCs can allow for the growth of tumors ([@bib9]). However, whether MSCs definitively enhance or inhibit tumor growth and cancer progression is still unresolved, since differences in the experimental design, cancer histologic cell type, and MSC isolation technique used can all affect the experimental outcome ([@bib23; @bib53]). Moreover, to date, studies on MSC and cancer interactions have largely focused on the homing of MSCs to tumors, rather than the immunological aspects of MSCs ([@bib13; @bib46; @bib52]). Although a considerable amount of data support MSC expansion of Tregs ([@bib50]), and these immunosuppressive T lymphocytes are also found in tumors, MDSCs appear to play a more crucial role in maintaining the profound immune suppression of the tumor niche ([@bib2; @bib34; @bib44; @bib55]). Our data suggest that through HGF and the consequent expansion of MDSCs, MSCs may play a role in maintaining tumor growth.

While the association of MDSCs in a wide range of cancers has been known for some time, the mechanisms involved in expansion of these immunomodulatory cells are just beginning to be unraveled. IL-6 has been reported to mediate the expansion of MDSCs, and this cytokine is known to be secreted by both MSCs and stromal cells ([@bib21; @bib32]). However, in this work, we did not find IL-6 to be involved. This may be due to the lower levels of this cytokine and the masking of its effects by the much higher levels of HGF in our system (see [Figure 3](#fig3){ref-type="fig"}B). Moreover, the strong association of MDSCs with cancer suggests that multiple and redundant pathways are likely involved ([@bib34; @bib16]). There is consensus, however, that STAT3 may be the final transcription factor involved in the expansion of MDSCs. Our finding that STAT3 activation is involved in HGF-mediated MDSC expansion further supports the importance of this molecule in inflammation and cancer ([@bib56]).

In summary, we found that HGF secreted by MSCs can lead to the expansion of MDSCs. MDSCs expanded by coculture with MSCs or addition of HGF are functional, expressing iNOS and ARG1, as well as harboring suppressive function and inducing Tregs. Mechanistically, the MSC-mediated expansion of MDSCs occurs via the HGF/c-Met axis, with the downstream involvement of STAT3. Our findings not only further demonstrate the strong immunoregulatory nature of MSCs, but also show the involvement of a mitogenic, noninflammatory molecule in the expansion of MDSCs.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

Human MSCs from bone marrow and placenta were cultured and expanded as we previously described ([@bib6; @bib54]). Human bone marrow MSCs were purchased from Cambrex and cultured according to manufacturer's instructions. For human placental MSCs, term placentas (38--40 weeks of gestation) from healthy donor mothers were obtained with informed consent according to the procedures of the institutional review board. The cells were isolated as previously described ([@bib54]). Differentiation studies were carried out as previously described ([@bib6; @bib29; @bib54]). Human PBLs were isolated from the buffy coat of healthy donor blood samples (Taiwan Blood Services Foundation, Taipei Blood Center, Taipei, Taiwan) obtained with informed consent according to the procedures of the institutional review board, and cultured as previously described ([@bib6; @bib29]).

Immunophenotyping {#sec4.2}
-----------------

Flow-cytometric analyses of cell surface markers were performed as previously described ([@bib6; @bib29; @bib54]). All antibodies were purchased from BD Biosciences, except for CD33 and CD11b (BioLegend), ARG1 (R&D Systems), iNOS (Abcam), and c-Met (eBiosciences). All analyses were done on a BD FACSCalibur flow-cytometric system (BD Biosciences).

Expansion of MDSCs {#sec4.3}
------------------

PBLs were cocultured with MSCs or cancer cell lines (10:1 ratio) for 3 days and then assessed for CD14^−^CD11b^+^CD33^+^ cells, which also served as the cell surface markers for fluorescence-activated cell sorting (FACS) of MDSCs with the BD Aria Cell Sorter (BD Biosciences). Instead of PBLs, some experiments were performed with CD14^−^ cells negatively selected with the use of magnetic beads (Miltenyi Biotec) according to the manufacturer's instructions. Transwell studies were performed as previously described using 24-well transwell inserts (0.4 μm pores; BD Falcon) with MSCs cultured on the culture plates below and PBLs cultured in the inserts ([@bib29]). Recombinant human HGF (R&D Systems) was added to PBLs at the indicated doses.

MDSC Suppression Analysis {#sec4.4}
-------------------------

Assessment of PBL cell division was performed as previously described ([@bib6]). Briefly, allogeneic PBLs were labeled with 2.5 μmol/l of the fluorescent dye carboxyfluorescein succinimidyl ester (CFSE; Molecular Probes/GIBCO-Invitrogen) for 10 min and then stimulated with anti-CD3/CD28 beads (GIBCO-Invitrogen). MSC-expanded MDSCs were FACS sorted for homogeneity and then cocultured with stimulated allogeneic PBL for 3 days at various effector-to-target (E:T) ratios. Flow-cytometric analysis was performed to assess for PBL cell division in terms of CFSE dye intensity.

Quantification of HGF Secretion {#sec4.5}
-------------------------------

Supernatants were collected from cell cultures for detection of HGF with the use of a commercially available ELISA kit (R&D Systems) according to the manufacturer's instructions.

RNAi Experiments {#sec4.6}
----------------

siRNAs specific for IL-6 and HGF were purchased from GIBCO-Invitrogen, and knockdown experiments were conducted according to the manufacturer's instructions. The efficiency of siRNA knockdown of MSC-secreted factors was verified by ELISA.

In Vivo Experiments {#sec4.7}
-------------------

All animal work was performed in accordance with protocols approved by the Animal Care and Use Committee of the National Health Research Institutes. Mice (4--8 weeks old) were obtained from the National Laboratory Animal Center of Taiwan (Taipei, Taiwan). Recombinant mouse HGF (100 ng; R&D Systems) was injected via the tail vein, and C57BL/6 mice were sacrificed 3 days after injection. Peripheral blood, bone marrow, and spleen were collected for flow-cytometric analysis of Gr-1^+^CD11b^+^ cells. For in vivo tumor studies, nude mice (BALB/c nu/nu) were inoculated subcutaneously with tumor cells (human colon cancer cell line HCT-116; 1 × 10^6^ cells) admixed with human MSCs (5 × 10^5^ cells at a 1:2 ratio to cancer cells) transfected with either control siRNA (NT siRNA) or HGF-specific siRNA (siHGF). The mice were sacrificed 3 weeks after inoculation, and tumors were excised and minced with scissors to obtain leukocytes, which were assessed for Gr-1^+^CD11b^+^ cells by flow-cytometric analysis. For c-Met inhibition studies, wild-type C57BL/6 mice were intraperitoneally injected with vehicle (DMSO, n = 3) or PHA-665752 (Tocris Bioscience), a c-Met inhibitor (0.15 mg, n = 3) as previously described ([@bib18]). The mice were sacrificed 5 days later and their livers and spleens were collected for flow-cytometric assessment of Gr-1^+^CD11b^+^ and Gr-1^+^CD11b^+^F4/80^−^ cells.

Statistical Analysis {#sec4.8}
--------------------

Statistical analysis was performed with SPSS 18.0 software (SPSS), with statistical significance defined as p \< 0.05. Values were expressed as the mean ± SEM. Student's t test was used for comparisons between two groups, and ANOVA was used for comparisons of multiple groups.

For further details regarding the materials and methods used in this work, see [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Supplemental Information {#app2}
========================
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![Characterization of Bone Marrow and Placental Multipotent MSCs\
(A and B) Surface marker profile (A) and trilineage differentiation phenotype (B) for bone marrow (BM) multipotent MSCs and placental MSCs (P-MSCs). Adipo, adipogenic lineage (stained with oil red O to assess for oil droplet formation); chondro, chondrogenic lineage (stained with Alcian blue to assess for the presence of glucosaminoglycans); osteo, osteogenic lineage (stained with alizarin red to assess calcium deposition). Scale bar: 200 μm.](gr1){#fig1}

![Human MSCs Expand the Number of Functional CD14^−^CD11b^+^CD33^+^ MDSCs in Allogeneic PBLs\
(A) Expansion of CD14^−^CD11b^+^CD33^+^ cells from PBLs by MSCs. Allogeneic PBLs (40 donors) were cocultured alone (top panel) or with MSCs (lower panel; three donors of BM-MSCs and four donors of P-MSCs; representative dot plots/ histogram shown). PBLs were gated on forward scatter (FSC)/side scatter (SSC) (R1, 100,000 events for all analyses), analyzed for CD14^−^ and CD11b^+^ (R2), and further analyzed for CD33^+^ (R3).\
(B) Quantification of percentage (left-side charts) and cell number (right-side charts) of PBL CD11b^+^ (upper graphs) or CD14^−^CD11b^+^CD33^+^ MDSCs (lower graphs) before and after coculture with MSCs. Averages ± SEM; 57 independent experiments; ^∗∗∗^p \< 0.001 compared with PBL only.\
(C) Suppressive function of MSC-induced MDSCs. Allogeneic PBLs (T, target cells; eight donors) were stained with CFSE for assessment of cell division and stimulated with anti-CD3/28 (α-CD3/28) without or with the addition of MSC-expanded MDSCs (from three donors) at various E:T ratios. Flow-cytometric analysis was performed to assess PBL cell proliferation/division as evidenced by decreasing CFSE staining. The chart on the right is a quantitative summary of experimental results; x axis: ratio of MSC-expanded MDSCs to activated PBL; y axis: percentage suppression of PBL proliferation by MSC-expanded MDSCs; eight independent experiments; ^∗^p \< 0.05 for trend. E, effector cells.\
(D and E) Expression of iNOS (D) and ARG1 (E) by MSC-expanded MDSCs (five donors of MSCs; representative histograms shown). Negatively selected CD14^−^ cells from PBLs (eight donors) were cultured alone (top panels) or with MSCs (lower panels). CD14^−^ cells were gated on FSC/SSC (R1), analyzed for CD11b^+^ and CD33^+^ (R2), and further analyzed for either (D) iNOS or (E) ARG1 (shaded gray areas in histogram; unfilled black line: isotype control). Average cell numbers ± SEM are indicated in the upper-right corner of the histogram; ^∗^p \< 0.05 comparing CD14^−^ + MSCs with CD14^−^ only.\
(F) Expansion of CD4^+^CD25^high^ Tregs by MSC-expanded MDSCs. CD14^−^CD11b^+^CD33^+^ MSC-expanded MDSCs (three donors) were FACS sorted and cocultured with anti-CD3/28-stimulated allogeneic PBLs (three donors) at various ratios and assessed for induction of CD4^+^CD25^high^ T cells. The chart on the right is a quantitative summary of the experimental results of three independent experiments. ^∗^p \< 0.05 compared with anti-CD3/28-activated PBL (leftmost bar).\
See also [Figure S1](#app2){ref-type="sec"}.](gr2){#fig2}

![MSC Expansion of MDSCs Is Mediated by Secreted HGF\
(A) MSC expansion of MDSCs is mediated by secreted factors. Allogeneic PBLs (five donors) were cocultured with MSCs either in direct contact (MSC; three donors) or separated by transwell (TW) and assessed for expansion of CD14^−^CD11b^+^CD33^+^ MDSCs; five independent experiments; ^∗^p \< 0.05 compared with PBL only; n.s., not significant.\
(B) Highly secreted factors of MSCs (four donors) as assessed by quantitative cytokine array. LAP, latency-associated peptide; SDF, stromal-derived factor.\
(C and D) Exogenous addition of recombinant HGF to PBLs (five donors) increases the (C) percentage of MDSCs (^∗^p \< 0.05 for trend) and (D) expression of iNOS (top panel) and ARG1 (lower panel) in HGF-expanded MDSCs (five donors; representative charts shown) as assessed by using negatively selected CD14^−^ cells that were first gated on FSC/SSC (R1), analyzed for CD11b^+^ and CD33^+^ (R2), and then further analyzed for either iNOS (top histogram, shaded gray area) or ARG1 expression (bottom histogram, shaded gray area). Unfilled black line: isotype control; p = 0.051 for comparison of average number of CD14^−^CD11b^+^CD33^+^ cells (±SEM) expressing iNOS (367 ± 39 without HGF treatment compared with 409 ± 46 with HGF treatment); p \< 0.05 for ARG1 expression (312 ± 53 without HGF treatment compared with 396 ± 56 with HGF treatment).\
(E) Suppression of anti-CD3/28-stimulated PBL proliferation by HGF-expanded MDSCs as assessed by flow-cytometric analysis of CFSE staining for cell division (n = 3; a representative chart is shown).\
(F) Knockdown of HGF secretion in MSCs with HGF-specific siRNA abrogates the expansion of MDSCs. Allogeneic PBLs (seven donors) were cocultured with MSCs (three donors) transfected with either NT siRNA or siHGF and assessed for CD14^−^CD11b^+^CD33^+^ cells. ^∗^p \< 0.05 compared with MSCs only (leftmost bar) or PBLs only (rightmost bar); n.s., not significant (NT siRNA compared with siHGF).\
See also [Figure S2](#app2){ref-type="sec"}.](gr3){#fig3}

![Cancer Cell-Secreted HGF and In Vivo Manipulation of HGF Expression in Mice Significantly Alter MDSC Numbers\
(A and B) Level of HGF secretion by MSCs, MG63 (osteosarcoma cell line), human embryonic stem cell-derived mesenchymal progenitors (EMPs), and JEG-3 (choriocarcinoma cell line) (A), and fold expansion of MDSCs (B) after coculture of the four cell types with PBLs (three donors; three independent experiments; ^∗^p \< 0.05 for trend).\
(C) Knockdown of HGF expression in MSCs significantly decreases tumor-associated Gr-1^+^CD11b^+^ cells. Tumor growth was induced in nude mice by inoculating human colon cancer cells admixed with MSCs transfected with either control NT siRNA (n = 5 mice) or siHGF (n = 5 mice). Tumor-associated leukocytes were assessed for Gr-1^+^CD11b^+^ cells by flow-cytometric analysis (see [Experimental Procedures](#sec4){ref-type="sec"}for detailed description); ^∗^p \< 0.05, NT siRNA compared with siHGF.\
(D) Gr-1^+^CD11b^+^ cells (%) in the spleen and liver of C57BL/6 (B6) and BALB/c mice (n = 3 mice for each group); ^∗^p \< 0.05, % of cells in liver compared with spleen.\
(E) Treatment of C57BL/6 mice with the c-Met inhibitor PHA-665752 (c-Met inh) significantly decreases hepatic but not splenic Gr-1^+^CD11b^+^F4/80^−^ cells (shown as a percentage of Gr-1^+^CD11b^+^ cells; average ± SEM; n = 3 mice for each group). ^∗^p \< 0.05 for c-Met inhibitor treatment versus no treatment (see [Experimental Procedures](#sec4){ref-type="sec"} for a detailed description).\
(F) Tail-vein injection of recombinant HGF (100 ng) into C57BL/6 mice and assessment of Gr-1^+^CD11b^+^ cells (fold change) in the peripheral blood, spleen, and bone marrow 1 day and 3 days after injection (n = 6 mice for each group); ^∗^p \< 0.05 compared with day 0.\
See also [Figure S3](#app2){ref-type="sec"}.](gr4){#fig4}

![Expansion of MDSCs by HGF Is Mediated via c-Met, Its Receptor, and Increased Phosphorylation of STAT3\
(A) Expression of c-Met on MDSCs as assessed by flow-cytometric analysis. PBLs (six donors) were first gated on FSC/SSC (R1), analyzed for CD11b^+^ and CD33^+^ (R2), and then further analyzed for c-Met expression (shaded gray area in histogram; unfilled black line: isotype control; the flow-cytometric analysis diagrams shown are representative). Right chart: quantification of mean fluorescent intensity (MFI); ^∗^p \< 0.05 compared with isotype control (Ctrl).\
(B) Involvement of c-Met in HGF-mediated expansion of MDSCs. PBLs (six donors) were blocked with isotype control antibodies (IsoAb) or c-Met blocking antibodies (anti-c-Met), treated with recombinant HGF (20 ng/ml), and assessed for expansion of CD14^−^CD11b^+^CD33^+^ cells. PBLs were first gated on FSC/SSC (R1), analyzed for CD14^−^ and CD11b^+^ (R2), and then further analyzed for CD33^+^ (R3). Average percentages and cell numbers ± SEM are indicated in dot plot diagrams (1.54% ± 0.20% and 1,544 ± 201 cells for isotype control). Charts on the right are quantitative summaries of the percentages (top right) and cell numbers (bottom right) of six independent experiments; ^∗^p \< 0.05 compared with PBL only or anti-c-Met.\
(C) Involvement of STAT3 in HGF-mediated expansion of MDSCs. Recombinant HGF (20 ng/ml) was added to negatively selected CD14^−^ leukocytes (eight donors) that were stained for CD11b, CD33, and pSTAT3. Control cells (no HGF treatment; black unfilled line in histogram) and HGF-treated cells (red unfilled line) were collected for assessment by flow cytometry at the indicated time points (shaded gray area: isotype control); average cell numbers ± SEM for control (C) and HGF treatment (H) are indicated below the histograms. The chart on the right is a quantitative summary of eight independent experiments; ^∗^p \< 0.05 and ^∗∗^p \< 0.005.\
(D) STAT3 inhibition abrogates HGF-mediated expansion of MDSCs. Recombinant HGF (20 ng/ml) was added to PBLs (six donors) with and without addition of cpd188 (STAT3 inhibitor) at the indicated doses and assessed by flow cytometry for MDSCs, with PBLs first gated on FSC/SSC (R1), analyzed for CD14^−^ and CD11b^+^ (R2), and then further analyzed for CD33^+^ (R3). Average percentages and cell numbers ± SEM are indicated in dot plot diagrams (1.37% ± 0.22% and 717 ± 108 cells for 5 μM cpd188). Charts on the right are quantitative summaries of the percentages (top right) and cell numbers (bottom right) of CD14^−^CD11b^+^CD33^+^ cells for six independent experiments. a, p \< 0.05 compared with PBL only; b, p \< 0.05 for trend; n.s., not significant for 10 μM cpd188 compared with PBL only.\
See also [Figures S4](#app2){ref-type="sec"} and [S5](#app2){ref-type="sec"}.](gr5){#fig5}

![Summary of MSC-Mediated Expansion of Functional MDSCs\
HGF secreted by MSCs binds to its cognate receptor, c-Met, expressed on CD14^−^ PBLs. This leads to increased pSTAT3, a critical transcription factor in MDSC expansion. Both MSC- and HGF-expanded MDSCs are functional, expressing ARG1 and iNOS, and inhibit allogeneic lymphocyte proliferation while increasing the number of immunomodulatory Tregs.](gr6){#fig6}
